Dirk Sibbing Shares a Recent ”Excellent Study” on Clopidogrel Versus Aspirin by Marco Valgimigli and Colleagues
Dirk Sibbing, Professor, Cardiologist and Angiologist at Privatklinik Lauterbacher Mühle and LMU Munich, reposted from Claudio Laudani on LinkedIn:
”Excellent study with clinically important results, especially in light of recent data at ESC 2025 in Madrid on hashtag#clopidogrel in secondary prevention for CAD patients after PCI. Valgimigli et al., Lancet 2025”
Read the full article here.
Article: Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis
Auhtors: Marco Valgimigli, Ki Hong Choi, Daniele Giacoppo, Felice Gragnano, Takeshi Kimura, Hirotoshi Watanabe, Hyo-Soo Kim, Jeehoon Kang, Kyung Woo Park, Alf-Åge Pettersen, Mark Woodward, Deepak L Bhatt, Paolo Calabrò, Dominick J Angiolillo, Roxana Mehran, Young Bin Song, Joo-Yong Hahn
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared a post on LinkedIn:
”Race has been shown to have a significant influence on clinical outcomes in patients with atherosclerotic cardiovascular disease.
However, the mechanisms behind such association are still poorly understood.
In this manuscript, we explored biological condition that may be responsible for such association, finding that among participant with atherosclerotic cardiovascular disease on chronic clopidogrel treatment, Black individuals have higher platelet reactivity (related to P2Y12 receptor activity) compared to non-Black individual.
In addition, we further confirmed the increased risk of MACE and myocardial infarction of Black individuals compared to non-black individuals among patients with coronary artery disease undergoing PCI.
These data highlight how further efforts are needed to reduce disparities between races, focusing on both healthcare access and biological process to guide the decision-making.”
Rad the full article here.
Article: Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel-Treated Participants
Authors: Luis Ortega-Paz, Cameron D. Thomas, Claudio Laudani, Salvatore Giordano, Francesco Franchi, Kayla R. Tunehag, Fabiana Rollini, Selina Durukan, Joseph S. Rossi, Maryam Farahmandsadr, George A. Stouffer, Latonya Been, Ellen C. Keeley, Julio D. Duarte, Amber L. Beitelshees, Craig R. Lee, Larisa H. Cavallari, Dominick J. Angiolillo
Stay updated on all science in the field of coagulation with Hemostasis Today.
-
Oct 19, 2026, 14:16Hyperfibrinolysis as an Underrecognized Cause of Bleeding
-
Oct 19, 2026, 13:36Shobhna Ladva: Aspen Pharma EME Raises Awareness of Blood Clot Risks During Hormonal Transitions
-
Oct 19, 2026, 13:11Giulia Furnari: Connecting With Global Hematology Experts at IACH 2026
-
Oct 19, 2026, 12:46Andrew Choong: Recognizing Thrombosis Before It Becomes Life-Threatening
-
Oct 19, 2026, 11:37Beth Faiman: APSHO Fellows Celebrated for Advancing Hematology and Oncology Practice
-
Oct 19, 2026, 11:26Emanuele Pacini: Myelodysplastic Syndromes Research Featured at JSH Annual Meeting in Kyoto
-
Oct 19, 2026, 10:57Jesmond Dalli: How Erythroblasts Shape Neutrophil Development and Function
-
Oct 19, 2026, 10:41Hisham Fahmi: SCD – Should Gene Editing Begin Before Organ Damage?
-
Oct 19, 2026, 10:33Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval